Christopher J. Fong
YOU?
Author Swipe
View article: A health-system-scale, episode-resolved multimodal atlas of cancer cachexia
A health-system-scale, episode-resolved multimodal atlas of cancer cachexia Open
Cancer cachexia is a wasting syndrome with outsized impact on morbidity and mortality. Neither the etiology of cachexia, nor its consequences on patient physiology and outcomes, are well-understood. Here, we repurposed longitudinal clinico…
View article: Germline landscape of high grade serous ovarian cancer across age groups: Is age just a number?
Germline landscape of high grade serous ovarian cancer across age groups: Is age just a number? Open
View article: Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival
Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival Open
View article: Short-term stability of the sputum microbiota in bronchiectasis and cystic fibrosis
Short-term stability of the sputum microbiota in bronchiectasis and cystic fibrosis Open
The microbiome in bronchiectasis shows day to day variability in sputum samples from people with bronchiectasis and cystic fibrosis. This should be taken into account in studies of the airway microbiome in chronic airway disease. ht…
View article: Shareable artificial intelligence to extract cancer outcomes from electronic health records for precision oncology research
Shareable artificial intelligence to extract cancer outcomes from electronic health records for precision oncology research Open
View article: Automated real-world data integration improves cancer outcome prediction
Automated real-world data integration improves cancer outcome prediction Open
The digitization of health records and growing availability of tumour DNA sequencing provide an opportunity to study the determinants of cancer outcomes with unprecedented richness. Patient data are often stored in unstructured text and si…
View article: DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism
DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism Open
Cancer-associated venous thromboembolism (VTE) is a major source of oncologic cost, morbidity and mortality. Identifying high-risk patients for prophylactic anticoagulation is challenging and adds to clinician burden. Circulating tumor DNA…
View article: Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers
Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers Open
View article: Supplementary Figure Legends from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Supplementary Figure Legends from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer Open
Supplementary Figure Legends
View article: Figure S2 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Figure S2 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer Open
CONSORT diagram
View article: Data from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Data from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer Open
The anti-HER2 antibody trastuzumab is standard care for advanced esophagogastric (EG) cancer with ERBB2 (HER2) amplification or overexpression, but intrinsic and acquired resistance are common. We conducted a phase II study of afati…
View article: Figure S1 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Figure S1 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer Open
Additional results for dual probe EGFR and ERBB2 FISH from Patients 9, 30 and 32.
View article: Figure S2 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Figure S2 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer Open
CONSORT diagram
View article: Figure S1 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Figure S1 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer Open
Additional results for dual probe EGFR and ERBB2 FISH from Patients 9, 30 and 32.
View article: Data from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Data from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer Open
The anti-HER2 antibody trastuzumab is standard care for advanced esophagogastric (EG) cancer with ERBB2 (HER2) amplification or overexpression, but intrinsic and acquired resistance are common. We conducted a phase II study of afati…
View article: Supplementary Tables S1-S10 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Supplementary Tables S1-S10 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer Open
Supplementary Tables S1-S10
View article: Supplementary Figure Legends from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Supplementary Figure Legends from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer Open
Supplementary Figure Legends
View article: Supplementary Tables S1-S10 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Supplementary Tables S1-S10 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer Open
Supplementary Tables S1-S10
View article: Ovarian cancer mutational processes drive site-specific immune evasion
Ovarian cancer mutational processes drive site-specific immune evasion Open
View article: Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors
Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors Open
View article: Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer Open
View article: Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients Open
View article: The context-specific role of germline pathogenicity in tumorigenesis
The context-specific role of germline pathogenicity in tumorigenesis Open
View article: Immune and malignant cell phenotypes of ovarian cancer are determined by distinct mutational processes
Immune and malignant cell phenotypes of ovarian cancer are determined by distinct mutational processes Open
High-grade serous ovarian cancer (HGSOC) is an archetypal cancer of genomic instability patterned by distinct mutational processes, intratumoral heterogeneity and intraperitoneal spread. We investigated determinants of immune recognition a…
View article: Patterns of Metastatic Disease in Patients with Cancer Derived from Natural Language Processing of Structured CT Radiology Reports over a 10-year Period
Patterns of Metastatic Disease in Patients with Cancer Derived from Natural Language Processing of Structured CT Radiology Reports over a 10-year Period Open
Background Patterns of metastasis in cancer are increasingly relevant to prognostication and treatment planning but have historically been documented by means of autopsy series. Purpose To show the feasibility of using natural language pro…
View article: Risk for development of active tuberculosis in patients with chronic airway disease—a systematic review of evidence
Risk for development of active tuberculosis in patients with chronic airway disease—a systematic review of evidence Open
Reports suggest an increased risk of tuberculosis (TB) in people with chronic airway diseases (CADs) such as chronic obstructive pulmonary disease (COPD), but evidence has not been systematically reviewed. We performed a systematic review …
View article: Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma
Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma Open
Purpose: We report our experience with next-generation sequencing to characterize the landscape of actionable genomic alterations in renal cell carcinoma (RCC). Experimental Design: A query of our institutional clinical sequencing database…
View article: Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients Open
Progression to metastatic disease remains the main cause of cancer death. Yet, the underlying genomic mechanisms driving metastasis remain largely unknown. Here, we present MSK-MET, an integrated pan-cancer cohort of tumor genomic and clin…
View article: Therapeutic Implications of Germline Testing in Patients With Advanced Cancers
Therapeutic Implications of Germline Testing in Patients With Advanced Cancers Open
PURPOSE Tumor mutational profiling is increasingly performed in patients with advanced cancer. We determined the extent to which germline mutation profiling guides therapy selection in patients with advanced cancer. METHODS Patients with c…
View article: A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response
A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response Open
There is conflicting data regarding the role of PBAF complex mutations and response to immune checkpoint blockade (ICB) therapy in clear cell renal cell carcinoma (ccRCC) and other solid tumors. We assess the prevalence of PBAF complex mut…